Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase

Antiviral Research

Volumn 97, Issue 3, 2013, Pages 356-368

  Winquist, Johan ^a   Abdurakhmanov, Eldar ^a   Baraznenok, Vera ^b   Henderson, Ian ^b   Vrang, Lotta ^b   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

Chemodynamics; HCV; Inhibitor; Kinetics; NS5B; Thermodynamics

Indexed keywords

FILIBUVIR; LOMIBUVIR; NONSTRUCTURAL PROTEIN 5B; TEGOBUVIR; VIRUS RNA;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME BINDING; HEPATITIS C VIRUS; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS; THERMOSTABILITY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BINDING SITES; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; KINETICS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84873050231     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.027     Document Type: Article

References (29)

1. World Health Organization HCV fact sheet, No. 164. 2011.
2. Beaulieu P.L. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection. IDrugs: The Investigational Drugs Journal 2010, 13:938-948.
3. Butt A.A., Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clinical Infectious Diseases: An Official Publication of The Infectious Diseases Society of America 2012, 54:96-104.
4. Chayama K., Hayes C.N. Hepatitis C virus: how genetic variability affects pathobiology of disease. Journal of Gastroenterology and Hepatology 2011, 26(Suppl. 1):83-95.
5. Danielson U.H. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Medicinal Chemistry 2009, 1:1399-1414.
6. Davis B., Thorpe I.F. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase. Proteins 2012.
7. Elinder M., Selhorst P., Vanham G., Öberg B., Vrang L., Danielson U.H. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-importance of slow dissociation and relaxation rates for antiviral efficacy. Biochemical Pharmacology 2010, 80:1133-1140.
8. Geitmann M., Dahl G., Danielson U.H. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. Journal of Molecular Recognition 2011, 24:60-70.
9. Geitmann M., Danielson U.H. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorganic & Medicinal Chemistry 2007, 15:7344-7354.
10. Geitmann M., Unge T., Danielson U.H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. Journal of Medicinal Chemistry 2006, 49:2367-2374.
11. Geitmann M., Unge T., Danielson U.H. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. Journal of Medicinal Chemistry 2006, 49:2375-2387.
12. Granich R., Crowley S., Vitoria M., Smyth C., Kahn J.G., Bennett R., Lo Y.R., Souteyrand Y., Williams B. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Current Opinion in HIV and AIDS 2010, 5:298-304.
13. Hebner C.M., Han B., Brendza K.M., Nash M., Sulfab M., Tian Y., Hung M., Fung W., Vivian R.W., Trenkle J., Taylor J., Bjornson K., Bondy S., Liu X., Link J., Neyts J., Sakowicz R., Zhong W., Tang H., Schmitz U. The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 2012, 7:e39163.
14. Imhof I., Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011, 53:1090-1099.
15. Legrand-Abravanel F., Nicot F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opinion on Investigational Drugs 2010, 19:963-975.
16. Li H., Tatlock J., Linton A., Gonzalez J., Jewell T., Patel L., Ludlum S., Drowns M., Rahavendran S.V., Skor H., Hunter R., Shi S.T., Herlihy K.J., Parge H., Hickey M., Yu X., Chau F., Nonomiya J., Lewis C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. Journal of Medicinal Chemistry 2009, 52:1255-1258.
17. Lo M.C., Aulabaugh A., Jin G., Cowling R., Bard J., Malamas M., Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Analytical Biochemistry 2004, 332:153-159.
18. Love R.A., Parge H.E., Yu X., Hickey M.J., Diehl W., Gao J., Wriggers H., Ekker A., Wang L., Thomson J.A., Dragovich P.S., Fuhrman S.A. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. Journal of Virology 2003, 77:7575-7581.
19. Markgren P.O., Lindgren M.T., Gertow K., Karlsson R., Hämäläinen M., Danielson U.H. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Analytical Biochemistry 2001, 291:207-218.
20. Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nature Protocols 2007, 2:2212-2221.
21. Pornillos O., Alam S.L., Rich R.L., Myszka D.G., Davis D.R., Sundquist W.I. Structure and functional interactions of the Tsg101 UEV domain. The Embo Journal 2002, 21:2397-2406.
22. Shih I.H., Vliegen I., Peng B., Yang H., Hebner C., Paeshuyse J., Purstinger G., Fenaux M., Tian Y., Mabery E., Qi X., Bahador G., Paulson M., Lehman L.S., Bondy S., Tse W., Reiser H., Lee W.A., Schmitz U., Neyts J., Zhong W. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrobial Agents and Chemotherapy 2011, 55:4196-4203.
23. Shuman C.F., Hämäläinen M.D., Danielson U.H. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. Journal of Molecular Recognition 2004, 17:106-119.
24. Simister P., Schmitt M., Geitmann M., Wicht O., Danielson U.H., Klein R., Bressanelli S., Lohmann V. Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. Journal of Virology 2009, 83:11926-11939.
25. Vliegen I., Paeshuyse J., De Burghgraeve T., Lehman L.S., Paulson M., Shih I.H., Mabery E., Boddeker N., De Clercq E., Reiser H., Oare D., Lee W.A., Zhong W., Bondy S., Purstinger G., Neyts J. Substituted imidazopyridines as potent inhibitors of HCV replication. Journal of Hepatology 2009, 50:999-1009.
26. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute 1989, 81:577-586.
27. Yamashita T., Kaneko S., Shirota Y., Qin W., Nomura T., Kobayashi K., Murakami S. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. The Journal of Biological Chemistry 1998, 273:15479-15486.
28. Yi G., Deval J., Fan B., Cai H., Soulard C., Ranjith-Kumar C.T., Smith D.B., Blatt L., Beigelman L., Kao C.C. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrobial Agents and Chemotherapy 2012, 56:830-837.
29. Zhukov A., Karlsson R. Statistical aspects of van't Hoff analysis: a simulation study. Journal of Molecular Recognition 2007, 20:379-385.